Bosentan 125 mg ( DrugBank: Bosentan )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	3

51. Scleroderma

---

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00319696 (ClinicalTrials.gov)	July 8, 2004	27/4/2006	Bosentan in Digital Ulcers	Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers	Digital Ulcers	Drug: Bosentan 62.5 mg;Drug: Bosentan 125 mg	Actelion	NULL	Completed	18 Years	N/A	All	116	Phase 3	United States;Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom
2	NCT02800993 (ClinicalTrials.gov)	October 2003	13/6/2016	Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma	A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis	Systemic Sclerosis;Digital Ulcers	Drug: Bosentan 62.5 mg;Drug: Bosentan 125 mg;Drug: Placebo	Actelion	NULL	Completed	18 Years	N/A	Both	188	Phase 3	United States;Canada
3	NCT00077584 (ClinicalTrials.gov)	October 2003	10/2/2004	Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma	A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis	Digital Ulcers;Systemic Sclerosis	Drug: Bosentan 62.5 mg;Drug: Bosentan 125 mg;Drug: Placebo	Actelion	NULL	Completed	18 Years	N/A	Both	188	Phase 3	United States;Canada